Australian Government - Department of Health

Medical Services Advisory Committee (MSAC)

1250 - Testing of the ALK gene in tumour material from patients with non-small cell lung cancer to determine eligibility for treatment with crizotinib

The documents on this page may not be accessible, should you require assistance accessing the information please contact the MSAC Secretariat.
Resubmission: Please see Application 1250.1
Application Number1250
Application NameDiagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent).
Description of Medical ServiceALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.
Description of Medical ConditionALK-positive advanced NSCLC.
Consultation Protocol28 May 2012 – 5 July 2012
PDF version Consultation Decision Analytic Protocol (DAP)
Word version Consultation Decision Analytic Protocol (DAP)
Final Protocol PDF version Final Decision Analytic Protocol (DAP)
Word version Final Decision Analytic Protocol (DAP)
Reports-
MSAC OutcomesPDF version Public Summary Document (PDF 247 KB)
Word version Public Summary Document (Word 150 KB)

Meetings for this Application

Meeting Type:Date:
PASC12 – 13 April 2012, 16 – 17 August 2012
ESC 10 – 11 October 2013
MSAC 28 November 2013

Page currency, Latest update: 20 April, 2015